Literature DB >> 1336008

Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione.

G Bogliun1, L Marzorati, G Cavaletti, L Frattola.   

Abstract

The use of high doses of cisplatin (DDP) in the treatment of different solid tumors is often prevented by the onset of a disabling sensory neuropathy. In an attempt to minimize DDP-induced neurotoxicity different schedules of DDP administration have been tested. Moreover, during the past few years some putative neuroprotective drugs have been reported as reducing DDP neurotoxicity. In this prospective, randomized study we evaluated in a series of 33 patients affected by relapsing ovarian cancer the effect on the sensory pathway of a non-conventional schedule of DDP administration as monochemiotherapy or in combination with one of the neuroprotective drugs (i.e. glutathione). The results of the neurophysiologic examinations performed before and immediately after chemotherapy suggest that these schedules besides being safe and effective in the treatment of the ovarian cancer, have an extremely low peripheral neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336008     DOI: 10.1007/bf02334967

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  17 in total

1.  Cisplatin neurotoxicity.

Authors:  J E Mollman
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

2.  Polyneuropathy induced by cisplatin.

Authors:  B W Ongerboer de Visser; G Tiessens
Journal:  Prog Exp Tumor Res       Date:  1985

Review 3.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

4.  Cisplatin neuropathy with Lhermitte's sign.

Authors:  J Dewar; H Lunt; D A Abernethy; P Dady; L F Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

5.  Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.

Authors:  R G van der Hoop; C J Vecht; M E van der Burg; A Elderson; W Boogerd; J J Heimans; E P Vries; J C van Houwelingen; F G Jennekens; W H Gispen
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

6.  Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin.

Authors:  G K Daugaard; J Petrera; W Trojaborg
Journal:  Acta Neurol Scand       Date:  1987-08       Impact factor: 3.209

7.  Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.

Authors:  G Cavaletti; L Marzorati; G Bogliun; N Colombo; M Marzola; M R Pittelli; G Tredici
Journal:  Cancer       Date:  1992-01-01       Impact factor: 6.860

8.  Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry.

Authors:  P J Dyck; W R Sherman; L M Hallcher; F J Service; P C O'Brien; L A Grina; P J Palumbo; C J Swanson
Journal:  Ann Neurol       Date:  1980-12       Impact factor: 10.422

9.  The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry.

Authors:  K Tomiwa; C Nolan; J B Cavanagh
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

10.  The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer.

Authors:  G Cavaletti; G Bogliun; L Marzorati; M Marzola; M R Pittelli; G Tredici
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

View more
  4 in total

1.  North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.

Authors:  Alexis D Leal; Rui Qin; Pamela J Atherton; Paul Haluska; Robert J Behrens; Charles H Tiber; Patanit Watanaboonyakhet; Matthias Weiss; Paul T Adams; Travis J Dockter; Charles L Loprinzi
Journal:  Cancer       Date:  2014-03-11       Impact factor: 6.860

Review 2.  Interventions for preventing neuropathy caused by cisplatin and related compounds.

Authors:  James W Albers; Vinay Chaudhry; Guido Cavaletti; Ross C Donehower
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 3.  Chemotherapy-induced peripheral neurotoxicity.

Authors:  Guido Cavaletti; Paola Marmiroli
Journal:  Nat Rev Neurol       Date:  2010-11-09       Impact factor: 42.937

Review 4.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.